Avalyn Pharma

Avalyn is a biopharmaceutical company dedicated to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other serious respiratory diseases. Their lead asset is inhaled pirfenidone (AP01), used for treating IPF. Avalyn has offices in Seattle and San Diego. An experienced clinical and inhaled product development team is rapidly advancing AP01 as a treatment for IPF, with additional candidate drugs in the pipeline for IPF and other severe respiratory conditions.